Imagine spending your whole adult life watching what you eat, faithfully taking a pill every morning, and still being told your cholesterol is too high. For millions of people, that’s not a hypothetical – it’s Tuesday. No matter how disciplined they are, their bodies are simply wired to produce more LDL cholesterol (the “bad” kind that clogs arteries) than any statin can reliably tame. The daily grind of chronic medication, repeat blood tests, and escalating cardiovascular risk hangs over them for decades.
Now, researchers believe a fundamentally different kind of cholesterol reduction treatment may be on the horizon – one that doesn’t ask you to take anything daily, monthly, or even yearly. Just once. That’s it.
The results turning heads right now come not from a new drug exactly, but from something far more precise: a therapy that edits the DNA inside your liver cells with the goal of permanently lowering your LDL cholesterol. Early trial data published in late May 2026 suggest that a single infusion can slash bad cholesterol by more than half, and in some patients, by considerably more. Scientists who have spent careers in cardiology are calling the results unlike anything they’ve seen before.
Why Standard Cholesterol Treatment Isn’t Enough for Everyone
Heart disease remains the leading cause of death for men, women, and people of most racial and ethnic groups, with one person dying every 34 seconds from cardiovascular disease in the US. The numbers behind that toll are staggering. In 2024 alone, heart disease caused 683,037 deaths in the United States – more than any other single condition. LDL cholesterol is one of its primary drivers, and yet for a large subset of patients, the standard tools simply don’t get the job done.
Familial hypercholesterolemia (FH) is a genetic disorder that affects about 1 in 311 people and significantly increases the risk of coronary artery disease at a younger age. If left untreated, heart attacks occur in 30% of women with FH by age 60, and in 50% of men with FH by age 50. FH is inherited, not lifestyle-driven. Because the underlying biochemistry is different in people with FH, their high cholesterol is less responsive to the methods that usually work for others – including dietary changes and statin tablets.
Statins are the backbone of LDL management for most people, and they work well in many cases. According to the American Heart Association, PCSK9 inhibitors help the liver remove more LDL from the blood – but even high-intensity statins can only do so much for patients with severe inherited forms of high cholesterol. As a Phase 3 trial researcher noted, “fewer than half of patients with established atherosclerotic cardiovascular disease currently reach LDL cholesterol goals.” Researchers have long argued that an oral or injectable therapy effective enough to change outcomes on a population level remains out of reach with current tools.
That’s the gap this new approach is trying to close – and if early data holds up in larger trials, it could change the entire logic of how we manage cholesterol.
What VERVE-102 Is and How It Works
Eli Lilly announced positive Phase 1b Heart-2 study results on May 25, 2026 for VERVE-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver and lower LDL cholesterol following a single infusion.
“Base editing” is a form of gene editing – think of it as a very precise find-and-replace tool for DNA. Rather than cutting the genome (which older gene-editing methods do), base editing makes a targeted chemical change to a single letter in the genetic code. VERVE-102 consists of a messenger RNA encoding an adenine base editor and a guide RNA targeting the PCSK9 gene. Both are encapsulated in a lipid nanoparticle and administered as a single intravenous infusion over approximately four hours.
Why target PCSK9? Turning off this gene lowers LDL cholesterol and triglycerides – two blood fats linked to heart disease. People born with a loss-of-function genetic mutation in ANGPTL3 have lower lifetime risk of heart disease with no apparent adverse consequences – a real-world clue that gave scientists the confidence to pursue this approach. Some individuals are simply born with PCSK9 naturally dialed down, and they tend to have low LDL for life with no obvious downside. The therapy is designed to give that same biological advantage to people who weren’t born with it.
The Heart-2 trial is evaluating VERVE-102 in adults with heterozygous familial hypercholesterolemia (HeFH) or premature coronary artery disease (CAD) – two groups who carry the heaviest cardiovascular burden and who most urgently need a cholesterol reduction treatment that goes beyond what daily pills can offer. VERVE-102 is administered as an intravenous infusion over the course of a few hours. Once. That’s the entire treatment.
The Trial Results: What the Data Shows
These data were presented as a late-breaking oral presentation at the European Atherosclerosis Society (EAS) Congress and simultaneously published in The New England Journal of Medicine.
It’s important to understand the context here: Heart-2 is an early-phase, open-label study in a small group of patients. The results are promising, but they are preliminary. Phase 1b trials are designed primarily to test safety and find the right dose, not to prove that a therapy works at scale. Heart-2 is an ongoing, open-label, single-ascending-dose Phase 1b study evaluating the safety, tolerability, and pharmacodynamic effects of VERVE-102, with this interim analysis including 35 participants who received a single intravenous infusion across six dose cohorts.
The results were dose-dependent – meaning higher doses produced greater reductions. Mean reductions in PCSK9 ranged from 51% at the lowest dose to 88% at the highest, with corresponding mean LDL reductions ranging from 9% at the lowest dose up to 62% at the 1.0 mg/kg dose. In absolute terms, the LDL reduction at the highest dose translated to a drop of 78 mg per deciliter. These are the best-case figures from the highest dose tested in a 35-person trial, and larger, longer, randomized studies will be needed before the full picture is clear.
Crucially, these weren’t short-lived effects. Follow-up was at least 28 days for all participants, with a subset followed for up to 18 months; as of the data cutoff of February 27, 2026, median follow-up was approximately nine months, and 15 participants had at least one year of follow-up. One infusion. Sustained results for at least a year and a half in the most closely followed patients – though the long-term picture beyond 18 months remains unknown.
As one senior Lilly executive put it, “twenty years ago, genetics showed us that people born with PCSK9 naturally turned off have low LDL-C for life and are remarkably protected from heart attack,” with the Heart-2 results providing early clinical evidence that a single dose of VERVE-102 may mimic those protective effects.
How Does This Compare to Existing Options?
Current injectable PCSK9-blocking medications – known as monoclonal antibodies – already exist and work well. The LDL reduction seen with VERVE-102 was similar to that generated by Amgen’s marketed cholesterol drug Repatha in people with genetic high cholesterol, although the two treatments have not been tested head to head. The key difference isn’t the magnitude of reduction – it’s the frequency. Repatha is injected every two weeks or monthly, indefinitely. VERVE-102 is a one-time infusion.
Research has shown that injectable PCSK9 therapies are rarely prescribed, partly because of high costs and insurance barriers – and even with price reductions and improved coverage, the majority of primary care physicians still don’t prescribe them, possibly because they are only available as injections. A single-dose approach removes the compliance problem entirely. There’s nothing to remember, nothing to refill, and no monthly injections to dread.
That said, this is still very early-stage science. “A single treatment that simultaneously lowered LDL cholesterol and triglycerides,” noted Luke Laffin, MD, lead study author and preventive cardiologist at the Cleveland Clinic – speaking about a related CRISPR trial – adding that if confirmed in larger studies, this one-and-done approach could dramatically reduce cardiovascular risk. The same caution applies equally to VERVE-102: Phase 1b data from 35 patients is a starting point, not a finish line.
For more on managing your heart health with today’s available tools, see this guide to learn about how somone could help manage high cholesterol.
Safety Profile So Far
Any treatment that edits your DNA raises a legitimate question: what are the risks? The early data is cautiously encouraging. VERVE-102 was reported as well tolerated, with no treatment-related serious adverse events or dose-limiting toxicities. Adverse events related to VERVE-102 included low-grade infusion-related reactions and fatigue. All participants received their full planned doses, and none withdrew from the trial.
Participants are expected to enroll in a long-term follow-up study for up to 15 years – a recognition that gene editing in humans requires watching carefully over the long arc. Editing DNA is not reversible. If an unintended effect emerged years later, you couldn’t simply stop taking a pill. That’s why the researchers and regulators are proceeding with appropriate caution, moving methodically through dose cohorts and following patients over extended periods.
The FDA has granted VERVE-102 Fast Track designation to reduce LDL-C in participants with hyperlipidemia and high lifetime cardiovascular risk. Fast Track designation means the FDA considers this a priority area – it doesn’t mean approval is imminent, but it does mean the regulatory process will move more efficiently as stronger data comes in. Lilly plans to begin enrolling the Phase 2 clinical study of VERVE-102 by the end of this year.
Patients currently managing high cholesterol with statins or other medications should not alter their treatment based on these early results. VERVE-102 is still an early-stage investigational treatment. It is not a cure, and it does not replace statins or doctor-guided cholesterol care.
The Bigger Picture in Cholesterol Research
VERVE-102 isn’t the only new approach generating attention. In a 15-patient, Phase 1 first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol and triglycerides in people with difficult-to-treat lipid disorders, according to a preliminary late-breaking science presentation at the American Heart Association’s Scientific Sessions 2025. That therapy, called CTX310, is an experimental CRISPR-Cas9 gene-editing treatment delivered as a one-time infusion that carries the CRISPR editing mechanism into the liver, where it switches off a gene called ANGPTL3 – and turning off this gene can lower LDL cholesterol and triglycerides, both linked to heart disease.
According to Cleveland Clinic cardiologist Luke Laffin, MD, the study’s co-first author, “gene editing is now feasible with CRISPR-based therapies for a variety of targets.” The study was reported as a late-breaking science presentation at the 2025 American Heart Association Scientific Sessions and simultaneously published in the New England Journal of Medicine. In the CTX310 trial, both LDL cholesterol and triglyceride levels were substantially reduced within two weeks after treatment and stayed low for at least 60 days – but like VERVE-102, this is Phase 1 data requiring much larger trials to confirm.
Meanwhile, for patients who can’t tolerate injections at all, oral options are also advancing. An experimental pill called enlicitide slashed levels of LDL cholesterol by up to 60%, according to a Phase 3 clinical trial published in The New England Journal of Medicine. The CORALreef Lipids trial was published February 4, 2026. The pill blocks the liver protein PCSK9, slowing the body’s ability to clear cholesterol from the blood – the same pathway as injectable PCSK9 inhibitors, but in pill form. Safety outcomes were comparable to placebo, with efficacy similar to monoclonal antibody PCSK9 inhibitors.
The convergence of these approaches – gene editing, base editing, and next-generation oral therapies – suggests the entire field of cholesterol management is moving quickly. The statin, for all its usefulness, may eventually be just the starting point rather than the destination
Read More: 3 Morning Habits to Avoid if You Have High Blood Pressure or Cholesterol
What This Means for You
If you or someone in your family has been diagnosed with familial hypercholesterolemia or early-onset coronary artery disease, the progress in this area matters more directly to you than to most. For now, VERVE-102 and therapies like it are still in clinical trials. They aren’t available outside of research settings, and no one should stop their current medication or alter their treatment plan based on early-phase trial data. The path from Phase 1b to an approved cholesterol reduction treatment runs through years of additional trials, safety monitoring, and regulatory review. That’s not pessimism – that’s the system working as it should.
What this research does confirm is that the scientific community has found a compelling new direction. The idea that a single infusion might safely rewrite the cholesterol trajectory of a person’s life for years – possibly permanently – is no longer science fiction. In 35 participants, a single intravenous dose produced dose-dependent mean PCSK9 reductions of 51 to 88% and LDL reductions up to 62%, sustained for up to 18 months. Those numbers, if they hold up across larger and more diverse populations, would represent a genuine shift in how cardiovascular medicine works. But that confirmation still lies ahead.
For now, the most practical step is the same as it’s always been: know your numbers, talk to your doctor about whether your current treatment is actually working, and stay informed as the research evolves. Fewer than half of patients with established cardiovascular disease currently reach their LDL cholesterol goals, and as one researcher put it, “an oral therapy this effective has the potential to dramatically improve our ability to prevent heart attacks and strokes on a population level.” Most people will be well-served by current tools. But for those who aren’t, the science developing right now offers a genuine reason for optimism – backed by data, not just hope.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: Another One-Time Infusion To Cut Cholesterol? Here’s How It Could Work.